Russia to postpone mandatory drug labeling for two years

30 November 2017
russia_moscow_large-1-

The Russian government has surprisingly decided to make concessions to domestic and global drugmakers operating in the country through the extension of the time, required for the mandatory labeling of drugs, reports The Pharma Letter’s local correspondent.

Elena Denisova, deputy head of the Department for the Development of the Pharmaceutical Industry at the Russian Ministry of Industry and Trade said yesterday the ministry is ready to review the timing of the introduction of drug labeling in the Russian pharmaceutical market.

On February 1 this year a voluntary experiment for the labeling of drugs in Russia officially started. In accordance with the recent amendments to the existing federal law "On the turnover of drugs in Russia," all drugs present in the Russian market should become subject to mandatory labeling by December 31, 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical